论文部分内容阅读
目的:为了研究早期使用rtPA(爱通立)对急性脑梗死病患的溶栓效果。方法:选取2011年8月到2012年8月在我院接受治疗的急性脑梗死病患60人,将这些病患随机分成治疗组与对照组,每组30人,为治疗组中的病患提供rtPA纤溶酶原激活物,与生理盐水混合后,静脉滴注,90分钟内将药物滴完,为对照组中的病患提供低分子右旋糖酐,并加入复方丹参药物,静脉滴注。第二天,CT检测头颅没有出血后,每隔12小时使用低分子肝素皮下注射,对比治疗前、治疗后第24小时、第21天ESS积分。结果:治疗组中病患第24小时与第21天的ESS积分明显优于治疗前,并且改善幅度明显优于对照组,P<0.01,具有显著的统计学差异意义。结论:在临床治疗急性脑梗死病患时,rtPA静脉溶栓药物治疗效果确切,而且安全性高,可以推广使用。
Purpose: To investigate the early thrombolytic effect of rtPA in patients with acute cerebral infarction. Methods: Sixty patients with acute cerebral infarction who were treated in our hospital from August 2011 to August 2012 were randomly divided into treatment group and control group, with 30 patients in each group as the treatment group Provide rtPA plasminogen activator, mixed with saline, intravenous drip, 90 minutes drip finished drug for the control group of patients with low molecular weight dextran, and add compound Salvia drugs, intravenous drip. The next day, CT skull subcutaneous injection of low molecular weight heparin was performed every 12 hours, compared with ESS scores on the 21st day and 24th day after treatment. Results: The scores of ESS on the 24th and 21st days in the treatment group were significantly better than those before treatment, and the improvement was significantly better than the control group, P <0.01, with significant statistical significance. Conclusion: In the clinical treatment of patients with acute cerebral infarction, rtPA intravenous thrombolytic therapy is effective and safe and can be widely used.